Galapagos NV (NASDAQ:GLPG) has earned a consensus recommendation of “Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $115.17.
GLPG has been the subject of several analyst reports. BTIG Research restated a “buy” rating and issued a $118.00 price objective on shares of Galapagos in a research note on Thursday. Stifel Nicolaus restated a “buy” rating and issued a $120.00 price objective on shares of Galapagos in a research note on Sunday, October 29th. BidaskClub upgraded Galapagos from a “hold” rating to a “buy” rating in a research note on Wednesday, January 31st. Zacks Investment Research upgraded Galapagos from a “sell” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, ValuEngine upgraded Galapagos from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd.
Galapagos (NASDAQ GLPG) traded down $0.88 during trading hours on Friday, hitting $108.83. The stock had a trading volume of 165,560 shares, compared to its average volume of 104,241. The stock has a market cap of $5,856.71, a price-to-earnings ratio of -118.29 and a beta of 1.85. Galapagos has a 52-week low of $67.26 and a 52-week high of $121.09.
WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/09/galapagos-nv-glpg-given-consensus-rating-of-buy-by-analysts.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.